Mitochondrial Disease-associated ImmunoDeficiencies
Condition(s) studied
Investigational drug(s) / intervention(s)
Patient cohort: Collection of 6 blood tubes at the inclusion visit.
Control cohort: Collection of 6 blood tubes at the inclusion visit.
Study summary
The study aims at characterizing the immune dysfunctions in patients with mitochondrial diseases. This has prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies to alleviate disease burden.
Eligibility
Primary outcome measure(s)
- Immunological parameters — Inclusion visit
Distribution of several quantitative immunological parameters at inclusion. The following parameters will be considered : Immunoglobulins in g/l (IgG subclasses, IgA, IgM) - Immunological parameters — Inclusion visit
Distribution of several quantitative immunological parameters at inclusion. The following parameters will be considered : multiplex flow cytometry panels (Th1, Th2, Th17, Tfh, T, B, monocytes) in fluorescence intensity unit
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Chu Bordeaux | Bordeaux | France | Recruiting |
| Hopital Toulouse | Toulouse | France | Not Yet Recruiting |
More University Hospital, Bordeaux trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06213103 on ClinicalTrials.gov ↗ ← All trials in France